ACUTE TOXICITY STUDIES OF METHACRYLIC ACID BASED COMPOSITE HYDROGEL OF SALVIA SPINOSA SEED MUCILAGE: A POTENTIAL NON-TOXIC CANDIDATE FOR DRUG DELIVERY
Source abstract
Abstract
Safety evaluation of a newly designed polymeric drug delivery system (DDS), with/without the addition of active pharmaceutical ingredients (APIs), is now mandatory for their regulatory approval for human use. Hence, Salvia spinosa seed mucilage/hydrogel (SSH) was treated with methacrylic acid (MAA) to synthesize a composite hydrogel (SSH-co-MAA). Acute oral and acute dermal toxicity studies of the SSH-co-MAA for API delivery were ascertained following OECD guidelines 420 and 402, respectively. Moreover, an ocular toxicity study was also performed and analyzed through Draize scale. Animals of two species, rodent (rat) and non-rodent (rabbit), were divided into four groups. Group A of both rats and rabbits was assigned as control and remained untreated. Meanwhile, groups B, C, and D were labelled as treated groups and received a single dose of SSH-co-MAA, i.e., 0.05, 0.3 and 2 g/kg body weight of the animal. During 14 days after the treatment, animal monitoring was done for behavioral changes, food and water intake, adverse effects, and mortality. All animals remained alive, with no statistically significant abnormality. Hematological and biochemical parameters of control and treated animals were analyzed after the completion of 14 days and found in harmonization. The vital organs of rats were removed to determine absolute organ weights. Histopathology of the vital organs of rats revealed normal cellular architecture, without any lesions. SSH-co-MAA was also free from dermal and ocular toxicity. The overall results of acute oral and dermal toxicity studies prove that SSH-co-MAA is safe, especially after oral administration. Hence, SSH-co-MAA can be used as a non-toxic excipient for drug delivery systems.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Hydrogels: synthesis, properties, applications · Advanced Drug Delivery Systems · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (26)
Show source-provided references
1. "1 R. E. Osterberg, C. C. Demerlis, D. W. Hobson and T. J. Mcgovern, Int. J. Toxicol., 30, 600 (2011), https://doi.org/10.1177/109158181142358210.1177/1091581811423582 ↗
2. 2 R. E. Osterberg and N. A. See, Int. J. Toxicol., 22, 377 (2003), https://doi.org/10.1177/10915818030220050710.1177/109158180302200507 ↗
3. 3 R. G. Sussman, B. D. Naumann, T. Pfister, C. Sehner, C. Seaman et al., Regul. Toxicol. Pharmacol., 79, S57 (2016), https://doi.org/10.1016/j.yrtph.2016.05.02310.1016/j.yrtph.2016.05.023 ↗
4. 4 M. Aslam, K. Barkat, N. S. Malik, M. S. Alqahtani, I. Anjum et al., Pharmaceutics, 14, 1218 (2022), https://doi.org/10.3390/pharmaceutics1406121810.3390/pharmaceutics14061218 ↗
5. 5 S. Kausar, A. Erum, U. R. Tulain, M. A. Hussain, M. Farid-ul-haq et al., Adv. Polym. Technol., 2021, 6634780 (2021), https://doi.org/10.1155/2021/663478010.1155/2021/6634780 ↗
6. 6 A. Ali, M. A. Hussain, M. T. Haseeb, S. N. A. Bukhari, T. Tabassum et al., J. Drug Deliv. Sci. Technol., 69, 103144 (2022), https://doi.org/10.1016/j.jddst.2022.10314410.1016/j.jddst.2022.103144 ↗
7. 7 A. Ali, M. A. Hussain, A. Abbas, M. T. Haseeb, I. Azhar et al., J. Mol. Liq., 376, 121438 (2023), https://doi.org/10.1016/j.molliq.2023.12143810.1016/j.molliq.2023.121438 ↗
8. 8 A. Ali, M. A. Hussain, A. Abbas, T. A. Khan, G. Muhammad et al., Cellulose Chem. Technol., 56, 239 (2022), https://doi.org/10.35812/CelluloseChemTechnol.2022.56.2210.35812/CelluloseChemTechnol.2022.56.22 ↗
9. 9 A. Ali, M. T. Haseeb, M. A. Hussain, U. R. Tulain, G. Muhammad et al., RSC Adv., 13, 4932 (2023), https://doi.org/10.1039/D2RA05240G10.1039/D2RA05240G ↗
10. 10 R. V. Kulkarni, S. Z. Inamdar, K. K. Das and M. S. Biradar, in "Polysaccharide Carriers Drug Delivery", edited by S. Maiti and S. Jana, Woodhead Publishing, 2019, pp. 155-177, https://doi.org/10.1016/B978-0-08-102553-6.00007-610.1016/B978-0-08-102553-6.00007-6 ↗
11. 11 M. K. Beliakova, A. A. Aly and F. A. Abdel-Mohdy, Starch/Stärke, 56, 407 (2004), https://doi.org/10.1002/star.20030024610.1002/star.200300246 ↗
12. 12 A. Ali, M. A. Hussain, M. T. Haseeb, S. N. A. Bukhari, G. Muhammad et al., Curr. Drug Deliv., 20, 292 (2023), https://doi.org/10.2174/156720181966622050920001910.2174/1567201819666220509200019 ↗
13. 13 A. Ali, M. A. Hussain, M. T. Haseeb, U. R. Tulain, M. Farid-ul-Haq et al., React. Funct. Polym., 182, 105466 (2023), https://doi.org/10.1016/j.reactfunctpolym.2022.10546610.1016/j.reactfunctpolym.2022.105466 ↗
14. 14 J. Irfan, M. A. Hussain, M. T. Haseeb, A. Ali, M. Farid-ul-Haq et al., RSC Adv., 11, 19755 (2021), https://doi.org/10.1039/D1RA02219A10.1039/D1RA02219A ↗
15. 15 M. Farid-ul-Haq, M. A. Hussain, M. T. Haseeb, M. U. Ashraf, S. Z. Hussain et al., RSC Adv., 10, 19832 (2020), https://doi.org/10.1039/D0RA03176C10.1039/D0RA03176C ↗
16. 16 M. B Bahadori, H. Valizadeh, B. Asghari, L. Dinparast, M. M. Farimani et al., J. Funct. Foods, 18, 727 (2015), https://doi.org/10.1016/j.jff.2015.09.01110.1016/j.jff.2015.09.011 ↗
17. 17 OECD (Organization for Economic Co-operation and Development) Guidelines for testing of chemicals. Acute oral toxicity-fixed dose procedure No. 420 (2001), https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecd_gl420.pdf
18. 18 OECD (Organization for Economic Co-operation and Development) guidelines for testing of chemicals. Acute dermal toxicity: fixed dose procedure No. 402 (2017), https://dx.doi.org/10.1787/9789264070585-en10.1787/9789264070585-en ↗
19. 19 J. H. Draize, J. Pharmacol. Exp. Ther., 82, 377 (1994), https://jpet.aspetjournals.org/content/82/3/377
20. 20 C. D. Klaassen and M. O. Amdur, "Casarett And Doull's Toxicology: The Basic Science Of Poisons", McGraw-Hill New York, 2013
21. 21 A. Diallo, K. Eklu-Gadegkeku, A. Agbono, K. Aklikokou, E. E. Creppy et al., Trop. J. Pharm. Res., 9, (2010), https://doi.org/10.4314/tjpr.v9i5.6105910.4314/tjpr.v9i5.61059 ↗
22. 22 E. Rivadeneyra-Domínguez, Y. Becerra-Contreras, A. Vázquez-Luna, R. Díaz-Sobac and J. F. Rodríguez-Landa, Toxicol. Rep., 5, 1124 (2018), https://doi.org/10.1016/j.toxrep.2018.11.00610.1016/j.toxrep.2018.11.006 ↗
23. 23 W. Miller and M. G. Graham, Patient Care-Darien Connecticut Then Montvale, 40, 19 (2006)
24. 24 C. C. Demerlis, A. Smith and D. R. Schoneker, in "Pharmaceutical Excipients: Properties, Functionality, and Applications in Research and Industry", John Wiley & Sons, Inc., 2016, pp. 241-267, https://doi.org/10.1002/9781118992432.ch610.1002/9781118992432.ch6 ↗
25. 25 M. A. Wallig, B. Bolon, W. M. Haschek and C. G. Rousseaux, "Fundamentals of Toxicologic Pathology", Academic Press, 2017
26. "